Substitute for PTO-1390 (Rev. 07-2005) Transmittal Letter to the United States Designated/Elected Office(DO/EO/US)Concerning a Submission Under 35 U.S.C. 371 Approved for use through 201 0007. Approved for use through 3/31/2007. OMB 0651-0021

	D 0001 001.		
U. S. PATENT AND TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE		ATTORNEY'S DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES		MC100YP	
DESIGNATED/ELECTED OFFICE (DO/EO/US)		U.S. APPLICATION NO. (If known, see 37 CFR 1.5)	
CONCERNING A FILIN		10/585144	
INTERNATIONAL APPLICATION NO.		PRIORITY DATE CLAIMED	
	06 January 2005	08 January 2004	
TITLE OF INVENTION CATHEPSIN CYSTEINE PROTEASE INHIBITORS			
APPLICANT(S) FOR DO/EO/US Christopher Bayly, Sheldon Crane and Serge Leger			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
1. X This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.			
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.			
3. This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must include items (5), (6), (9) and (21) indicated below.			
4. X The US has been elected (PCT Article 31).			
5. A copy of the International Application as filed [35 U.S.C. 371(c)(2)]			
a. is attached hereto (required only if not communicated by the International Bureau).			
b. X has been communicated by the International Bureau.			
c. is not required, as the application was filed in the United States Receiving Office (RO/US).			
6. An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)]. a. is attached hereto			
	ubmitted under 35 U.S.C. 154(d)(4).		
7. Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)]. a. are attached hereto (required only if not communicated by the International Bureau).			
b. have been communicated by the International Bureau.			
c. have not been made; however, the time limit for making such amendments has NOT expired.			
d. X have not been made and will not be made.			
8. An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].			
9. An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].			
10. An English language translation Article 36 [35 U.S.C. 371(c)(		Preliminary Examination Report under PCT	
Items 11 to 20 below concern other document(s) or information included:			
11. An Information Disclosure St	tatement under 37 CFR 1.97 and 1.98.		
is included.	recording. A separate cover sheet in c	compliance with 37 CFR 3.28 and 3.31	
13. A preliminary amendment.			
14. An Application Data Sheet under 37 CFR 1.76.			
15. A substitute specification.			
16. A power of attorney and/or change of address letter.			
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.			
18. A second copy of the published International Application under 35 U.S.C.154(d)(4).			
19. A second copy of the English language translation of the international application under 35 U.S.C.154(d)(4).			
20. Uther items or information:			

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United Suited Designated Elected Office (DO/EO/US) Concerning a Submission of the 35 U.S.C. 371" Approved for use through 3/31/2007. OMB 0651-0021 INTERNATIONAL APPLICATION NO. ATTORNEY'S DOCKET NUMBER U.S. APPLICATION NO. (If known, see 37 CFR 1.5) MC100YP PCT/CA2005/000008 The following fees are submitted: PTO USE ONLY CALCULATIONS 21. Basic national fee......\$300 \$300.00 Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)......\$0 All other situations.....\$200 Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)......\$0 Search fee [37 CFR 1.445(a)(2)] has been paid on the international application to the USPTO as an \$400.00 International Searching Authority......\$100 International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB ......\$400 TOTAL OF 21, 22 and 23= \$700.00 Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof. Number of each additional 50 or fraction **Total Sheets** Extra Sheets **RATE** thereof (round up to a whole number) -100 = 10 **/50** 0 = 0\$250.00 \$0.00 Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date [37 CFR 1.492(e)]. **NUMBER FILED NUMBER EXTRA RATE** CLAIMS Total Claims \$0.00 X 12 -20 =0 \$50.00 X Independent Claims \$0.00 \$200.00 - 3 = 0 MULTIPLE DEPENDENT CLAIM(S) (if applicable) \$360.00 \$700.00 TOTAL OF ABOVE CALCULATIONS (SUBTOTAL) Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest + claimed priority date (37 CFR 1.492(f)). = \$700.00 TOTAL NATIONAL FEE Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).\$40.00 per property. TOTAL FEES ENCLOSED \$700.00 Amount to be refunded: Amount to be charged: A check in the amount of \$ \_\_\_\_\_ to cover the above fees is enclosed. Please charge my Deposit Account No. 13-2755 in the amount of \$700.00 to cover the above fees. A duplicate copy of this sheet is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to the Deposit Account No. 13-2755. A duplicate copy of this sheet is enclosed. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the International Application to pending status. SEND ALL CORRESPONDENCE TO: Customer No. 000210 MERCK & CO., INC. Patent Department, RY60-30 P.O. Box 2000 126 East Lincoln Avenue Rahway, New Jersey 07065-0970 Dianne Brown **NAME** DATE: June 29, 2006 42,068 PHONE #: (732) 594-1249 REGISTRATION NUMBER

## 10/585144 iAP20Rec'ci PCT/PTO 29 JUN 2006

## Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

International Appln No.:	PCT/CA2005/000008  06 January 2005	
International Filing Date:		
Priority Date:	08 January 2004	
Title:	CATHEPSIN CYSTEINE PROTEASE INHIBITORS	
	_	
Inventors:	Christopher Bayly, Sheldon Crane and Serge Leger	

**MC100YP** 

**Attorney Docket No.:** 

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT June 29, 2006

EXPRESS MAIL NO. EV 660610875 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.

MAILED BY

DATE June 29, 2006